First‐in‐human outpatient management of recurrent NMIBC with the Multi4 instrument
BJU International · 2026-11 · 138 (5) · 867-876
DOI: 10.1111/bju.70445 ↗Kurz gefasst
Fachartikel in der Zeitschrift BJU International, online erschienen am 11.09.2026. Verfasst von Miden Melle-Hannah und 4 weiteren Autor:innen. Beteiligte Einrichtung: Multi4 Medical AB, Gothenburg, Sweden. Hauptthemen laut MEDLINE: Non-Muscle Invasive Bladder Neoplasms, Neoplasm Recurrence, Local. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: VINNOVA, Eurostars, European Innovation Council (EIC) Accelerator.
Abstract (Originalsprache)
Objectives
To evaluate the feasibility, safety and diagnostic performance of outpatient management of recurrent non‐muscle‐invasive bladder cancer (NMIBC) under local anaesthesia using the Multi4 instrument, a series of preclinical studies were performed followed by a first‐in‐human clinical investigation. NMIBC is associated with frequent recurrence, requiring repeated transurethral resection of the bladder (TUR‐B) under anaesthesia, resulting in substantial healthcare burden. The Multi4 instrument integrates local anaesthesia injection, diathermy biopsy, coagulation and automated tissue retrieval. The primary objective was to determine whether Multi4 provides histologically evaluable biopsies in an outpatient setting, and secondary objectives included safety, usability, patient‐reported outcomes and health‐economic impact.
Methods
Preclinical in vivo evaluation was performed in 13 pigs to assess safety, biopsy quality, coagulation efficacy and perforation risk. A prospective, open‐label, single‐arm clinical investigation enrolled 18 adults with recurrent Ta/T1 NMIBC (≤10 mm lesions). Procedures were performed under local anaesthesia using flexible cystoscopy. The primary endpoint was the proportion of evaluable biopsies. Secondary endpoints included adverse events, usability, pain (0–10 scale), EQ‐5D and cost comparison versus standard TUR‐B. Diagnostic yield was also assessed at the patient level.
Results
A total of 550 porcine biopsies demonstrated immediate haemostasis and preserved tissue architecture suitable for histological assessment. Perforation occurred after 7–11 sequential biopsies at the same location, indicating a wide safety margin. Clinically, 134/145 biopsies (92%) were evaluable and the primary endpoint was met. Diagnostic yield per patient was 89%. No device‐related adverse events or Clavien–Dindo complications occurred. All procedures were completed under local anaesthesia without conversion to standard TUR‐B or use of additional instruments. The median pain score was 0.5/10. Estimated per‐procedure cost reduction was 73–89% versus TUR‐B.
Conclusions
Multi4 enables feasible and safe outpatient biopsy and lesion management of small recurrent NMIBC under local anaesthesia with substantially reduced resource use while maintaining diagnostic reliability.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Multi4 Medical AB, Gothenburg, Sweden.
- Department of Urology, Institute of Clinical Sciences, Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden.
- Department of Urology, Sahlgrenska University Hospital, Gothenburg, Sweden.
- RISE Research Institutes of Sweden, Life Science, Medical Device and Diagnostics, Borås, Sweden.
- Department of Clinical Pathology, Sahlgrenska University Hospital, Gothenburg, Sweden.
- Sahlgrenska Center for Cancer Research, University of Gothenburg, Sahlgrenska Academy, Gothenburg, Sweden.
ORCID-Profile: Henrik Kjölhede, Martin E Johansson, Joakim Håkansson
Förderung
- VINNOVA
- Eurostars
- European Innovation Council (EIC) Accelerator
Zitieren
APA
Melle-Hannah, M., Kjölhede, H., Bäckdahl, H., Johansson, M. E., & Håkansson, J. (2026). First‐in‐human outpatient management of recurrent NMIBC with the Multi4 instrument. BJU International, 138(5), 867-876. https://doi.org/10.1111/bju.70445
Vancouver
Melle-Hannah M, Kjölhede H, Bäckdahl H, Johansson ME, Håkansson J. First‐in‐human outpatient management of recurrent NMIBC with the Multi4 instrument. BJU International. 2026;138(5):867-876. doi:10.1111/bju.70445
BibTeX
@article{MelleHannah2026,
author = {Melle-Hannah, Miden and Kjölhede, Henrik and Bäckdahl, Henrik and Johansson, Martin E and Håkansson, Joakim},
title = {First‐in‐human outpatient management of recurrent NMIBC with the Multi4 instrument},
journal = {BJU International},
year = {2026},
volume = {138},
number = {5},
pages = {867--876},
doi = {10.1111/bju.70445}
}
EUVIMED